MEI Pharma, Inc.
3611 Valley Centre Drive, Suite #500
About MEI Pharma, Inc.
MEI Pharma is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's portfolio of drug candidates includes Pracinostat, a potential best-in-class, oral HDAC inhibitor currently in Phase II clinical studies for advanced hematologic diseases. The Company is also developing ME-344, a novel mitochondrial inhibitor that has shown evidence of clinical activity in refractory solid tumors, and ME-401 (formerly PWT143), a highly selective, oral PI3K delta inhibitor. For more information, please visit www.meipharma.com.
CEO: Daniel Gold, PhD
Please click here for clinical trial information.
Please click here for Mei Pharma job opportunities.
296 articles with MEI Pharma, Inc.
Marshall Edwards, Inc. Announces First Patient Dosed in Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
Marshall Edwards, Inc. Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
Marshall Edwards, Inc. Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
Marshall Edwards, Inc. Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
Marshall Edwards, Inc. Adds Former Genentech Head of Medical Affairs Robert Mass as Chief Medical Officer
Marshall Edwards, Inc. to Report New Data on Mitochondrial Inhibitor Program at American Association for Cancer Research Annual Meeting
Marshall Edwards, Inc. Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
Marshall Edwards, Inc. Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells